



Prothena Corporation plc  
Investor Relations Department  
331 Oyster Point Blvd  
South San Francisco, CA 94080  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: PRTA

Last Trade:	53.03
Trade Time:	4:00 PM ET Jun 27, 2017
Change:	-4.47  (-7.774%)
Day Range	52.89 - 57.21
52-Week Range	34.30 - 68.18
Volume	253,602

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 12, 2017*

[Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer](#)

*May 16, 2017*

[Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer](#)

*May 9, 2017*

[Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update](#)

*May 2, 2017*

[Prothena to Report First Quarter 2017 Financial Results on May 9](#)

*Apr 26, 2017*

[Prothena to Participate in the Deutsche Bank 42nd Annual Health Care Conference](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Feb 27, 2017*

[Annual Report \(10-K\)](#)

*Mar 31, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 2, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 2, 2016*

[Quarterly Report \(10-Q\)](#)